Compare Surrozen, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 164 Million (Micro Cap)
6.00
NA
0.00%
3.41
86.05%
-6.99
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
22 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
68.78%
0%
68.78%
6 Months
94.24%
0%
94.24%
1 Year
87.89%
0%
87.89%
2 Years
141.48%
0%
141.48%
3 Years
2698.26%
0%
2698.26%
4 Years
-41.46%
0%
-41.46%
5 Years
-86.35%
0%
-86.35%
Surrozen, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-42.83%
EBIT Growth (5y)
-290.03%
EBIT to Interest (avg)
-27.19
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-17.70
Sales to Capital Employed (avg)
0.45
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
72.20%
ROCE (avg)
0
ROE (avg)
58.85%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
12.83
EV to EBIT
1.07
EV to EBITDA
1.12
EV to Capital Employed
0.29
EV to Sales
-2.38
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
27.39%
ROE (Latest)
214.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 3 Schemes (3.38%)
Foreign Institutions
Held by 3 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.90
-8.70
-2.30%
Interest
0.00
0.00
Exceptional Items
31.50
-15.30
305.88%
Consolidate Net Profit
21.80
-25.30
186.17%
Operating Profit Margin (Excl OI)
-9,172.90%
0.00%
-917.29%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 186.17% vs -169.15% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
10.70
0.00
Operating Profit (PBDIT) excl Other Income
-24.10
-41.10
41.36%
Interest
0.00
0.00
Exceptional Items
-38.20
-2.50
-1,428.00%
Consolidate Net Profit
-63.60
-43.00
-47.91%
Operating Profit Margin (Excl OI)
-2,396.90%
0.00%
-239.69%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -47.91% vs -19.44% in Dec 2023
About Surrozen, Inc. 
Surrozen, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






